Tirzepatide Scores Win in Second Obesity Trial, SURMOUNT-2

The "twincretin" tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.
Medscape Medical News

source https://www.medscape.com/viewarticle/991277?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?